NCT01451424View on ClinicalTrials.gov

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions
Uterine Fibroids
Interventions
DRUG

Proellex

vaginal suppository, daily, for 12 weeks

Trial Locations (2)

33169

Cetero Research, Miami Gardens

77030

Advances in Health, Houston

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01451424 - Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | Biotech Hunter | Biotech Hunter